Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial-Reference-Cited by-同舟云学术

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Published:2020-07-16 Issue:18 Volume:126 Page:4156-4167
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Motzer Robert J.¹^ORCID,Escudier Bernard²,George Saby³,Hammers Hans J.⁴,Srinivas Sandhya⁵,Tykodi Scott S.⁶,Sosman Jeffrey A.⁷,Plimack Elizabeth R.⁸,Procopio Giuseppe⁹^ORCID,McDermott David F.¹⁰,Castellano Daniel¹¹,Choueiri Toni K.¹²^ORCID,Donskov Frede¹³,Gurney Howard¹⁴,Oudard Stéphane¹⁵,Richardet Martin¹⁶,Peltola Katriina¹⁷,Alva Ajjai S.¹⁸,Carducci Michael¹⁹,Wagstaff John²⁰^ORCID,Chevreau Christine²¹^ORCID,Fukasawa Satoshi²²,Tomita Yoshihiko²³,Gauler Thomas C.²⁴,Kollmannsberger Christian K.²⁵,Schutz Fabio A.²⁶,Larkin James²⁷,Cella David²⁸,McHenry M. Brent²⁹,Saggi Shruti Shally³⁰,Tannir Nizar M.³¹

Affiliation:

1. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York

2. Department of Medical Oncology Gustave Roussy Villejuif France

3. Department of Medicine Roswell Park Cancer Institute Buffalo New York

4. Division of Hematology and Oncology UT Southwestern Kidney Cancer ProgramDallas Texas

5. Stanford Cancer Institute Stanford University Medical Center Stanford California

6. Department of Medicine University of Washington and Fred Hutchinson Cancer Research Center Seattle Washington

7. Department of Hematology/Oncology Northwestern University Medical Center Chicago Illinois

8. Department of Hematology/Oncology Fox Chase Cancer Center Philadelphia Pennsylvania

9. Fondazione Istituto Nazionale Tumori Milan Italy

10. Beth Israel Deaconess Medical Center, Dana‐Farber/Harvard Cancer Center Boston Massachusetts

11. Oncologia MedicaHospital Universitario 12 De Octubre Madrid Spain

12. Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts

13. Department of Oncology Aarhus University Hospital Aarhus Denmark

14. Department of Medical Oncology Westmead Hospital and Macquarie University Westmead New South Wales Australia

15. Service de Cancérologie Médicale Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris Paris France

16. Fundacion Richardet LongoInstituto Oncologico de Cordoba Cordoba Argentina

17. Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

18. Division of Hematology and Oncology University of Michigan Ann Arbor Michigan

19. Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins Medicine Baltimore Maryland

20. South West Wales Cancer Institute and Swansea University College of Medicine Swansea United Kingdom

21. Institut Claudius Regaud Institut Universitaire du Cancer de Toulouse ‐ Oncopole Toulouse France

22. Prostate Center and Division of Urology Chiba Cancer Center Chiba Japan

23. Department of Urology, Department of Molecular Oncology Niigata University Graduate School of Medical and Dental Sciences Niigata Japan

24. Department of Medicine University Hospital Essen, University of Duisburg‐Essen Duisburg Germany

25. Division of Medical Oncology BC Cancer–Vancouver Cancer Centre Vancouver British Columbia Canada

26. Beneficencia Portuguesa de São Paulo São Paulo Brazil

27. Royal Marsden Hospital NHS Foundation Trust London United Kingdom

28. Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine Northwestern University Chicago Illinois

29. Department of Biostatistics Bristol Myers Squibb Princeton New Jersey

30. Department of Clinical Trials Bristol Myers Squibb Princeton New Jersey

31. Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas

Funder

Bristol-Myers Squibb

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33033

Reference25 articles.

1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

3. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

4. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study;Cancer Medicine;2024-09

2. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma;New England Journal of Medicine;2024-08-22

3. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab;Immunotherapy;2024-08-19

4. Renal cell carcinoma;The Lancet;2024-08

5. Renal cancer: signaling pathways and advances in targeted therapies;MedComm;2024-08